Match each clinical scenario involving the use of a rheumatologic medication to its most critical associated toxicity, pharmacological interaction, or pre-treatment screening requirement.
- A patient with established rheumatoid arthritis begins treatment with a pyrimidine synthesis inhibitor. Months later, she decides to pursue pregnancy, necessitating an accelerated drug elimination protocol.Risk of prolonged teratogenicity due to extensive enterohepatic circulation; requires cholestyramine washout before attempting pregnancy.
- An individual diagnosed with granulomatosis with polyangiitis is scheduled to receive a chimeric monoclonal antibody targeting CD20 to induce disease remission.Risk of severe viral reactivation, including progressive multifocal leukoencephalopathy; requires screening for hepatitis B serologies prior to initiation.
- A patient with a history of recurrent gouty arthritis managed with daily allopurinol is evaluated for the addition of a purine analog immunosuppressant.Risk of life-threatening pancytopenia due to shunting toward toxic metabolites; requires avoiding concurrent use with xanthine oxidase inhibitors.
- A recently diagnosed patient with systemic lupus erythematosus starts a cornerstone antimalarial therapy known to reduce disease flares and improve long-term survival.Risk of irreversible retinal toxicity culminating in bull's-eye maculopathy; requires baseline and regular follow-up optical coherence tomography.
- A patient with severe rheumatoid arthritis is treated with a biologic therapy targeting tumor necrosis factor alpha. Several months later, the patient develops a chronic cough, night sweats, and apical lung cavitations.Risk of impaired granuloma formation leading to latent tuberculosis reactivation; requires screening with an interferon-gamma release assay prior to use.
Answer
The correct matching pairs are: Leflunomide with teratogenicity requiring cholestyramine washout; Rituximab with hepatitis B reactivation risk; Azathioprine with life-threatening pancytopenia risk when combined with allopurinol; Hydroxychloroquine with irreversible retinal toxicity risk; and TNF-alpha inhibitors with latent tuberculosis reactivation risk.
Each rheumatologic medication possesses a highly specific toxicity profile and mechanism of action that dictates its clinical management. Leflunomide requires a cholestyramine washout for pregnancy due to its long half-life. Rituximab profoundly depletes B cells, risking severe viral reactivation like HBV. Azathioprine metabolism is directly blocked by allopurinol, leading to severe pancytopenia. Hydroxychloroquine causes dose-dependent retinal toxicity requiring specialized OCT screening. Lastly, TNF-alpha inhibitors disrupt maintaining granulomas, necessitating screening for latent tuberculosis.
Step-by-Step Solution
Key Concept
Adverse effects, drug interactions, and pre-treatment screening requirements for disease-modifying antirheumatic drugs (DMARDs) and biologic agents.